When it comes to your hard-earned money, you have a lot of choices about where to spend it. If your physician prescribes a new branded drug, though, you and your insurance company have few options.Patent-protected exclusivity is the reason pharmaceutical stocks are known for delivering reliably growing dividend payments. Unfortunately, some of Pfizer's (PFE 1.08%) most important patents are expiring soon.Shares of Pfizer have been beaten down about 60% from their previous peak in 2021. The price is way down ...

Dogwood Therapeutics (DWTX) Conference June 11, 2025 09:15 AM ET Speaker0 Of our June 2025 SmallCap Conference. I'm Alex Antman, and I serve as an equity research analyst here at Sidoti and Company. Today, we're pleased to be in conversation with CEO and Chairman, Greg Duncan, of Dogwood Therapeutics, ticker DWTX. During the presentation, please feel welcome to submit questions using the Zoom Q and A interface at the bottom of your screen. After the presentation, we'll open to your questions. And with that, ...

Core Viewpoint - Viatris Inc. (VTRS) reported better-than-expected first-quarter adjusted earnings of 50 cents per share, surpassing the Zacks Consensus Estimate of 49 cents, although down from 67 cents per share in the same quarter last year [1][15] Financial Performance - Total revenues for the quarter were $3.25 billion, reflecting an 11% year-over-year decline, but still exceeding the Zacks Consensus Estimate of $3.23 billion [1][15] - Adjusted gross margin decreased to 55.9% from 58.8% year-over-year [10] Sales Breakdown - Sales from Developed Markets were $1.9 billion, down 3% on a divestiture-adjusted operational basis, missing the Zacks Consensus Estimate of $1.93 billion [4] - Emerging Markets generated $519.9 million in sales, down 5% on a divestiture-adjusted operational basis, but beating the Zacks Consensus Estimate of $464 million [5] - Sales from Japan, Australia, and New Zealand (JANZ) totaled $276.1 million, down 6% and missing the Zacks Consensus Estimate of $309 million [5] - Greater China sales increased by 4% to $555.5 million, surpassing the Zacks Consensus Estimate of $553 million [5] Product Category Performance - Revenues from Brands decreased by 8% to $2.1 billion, but increased by 3% on a divestiture-adjusted operational basis [6] - Lipitor sales were $388 million, relatively flat year-over-year, while Norvasc and Lyrica sales declined [6] - Generics revenue was $1.1 billion, down 16%, with an operational decline of 11% [7][9] Future Guidance - Viatris maintains its total revenue guidance for 2025 at $13.5-$14 billion and adjusted earnings per share guidance at $2.16-$2.30, updated from a previous range of $2.12-$2.26 [12] Research and Development Updates - Positive results were reported from phase III studies for Effexor and a novel formulation of meloxicam, with plans to submit a new drug application to the FDA by the end of 2025 [13][14]

Milan, Italy, May 8, 2025 – Sibylla Biotech today announced the appointment of Dieter Weinand as Chairman of its Board of Directors. Mr. Weinand is an industry veteran, boasting over 35 years in the pharmaceutical sector, including leading business units and drug commercialization initiatives at global organizations. His background includes serving as President, CEO and Chairman of the Board of Bayer Pharmaceuticals AG. At Sibylla, Mr. Weinand’s profound knowledge will guide the Board as the company advance ...

Things were going great, right until the point when they weren't.Few would dispute that Pfizer (PFE 0.63%) is an icon within the pharmaceutical world. And, giving credit where it's due, the drugmaker largely led the charge against the COVID-19 pandemic with both a vaccine and treatment.Anyone keeping tabs on this ticker of late, however, likely knows it's also been a disappointment since its contagion-driven peak. Indeed, thanks to more than a 60% pullback from its late-2021 high, investors that committed $ ...